Combination of letrozole, metronomic cyclophosphamide and sorafenib is well-tolerated and shows activity in patients with primary breast cancer

L. Bazzola, C. Foroni, D. Andreis, V. Zanoni, M. R. Cappelletti, G. Allevi, S. Aguggini, C. Strina, M. Milani, S. Venturini, F. Ferrozzi, R. Giardini, R. Bertoni, H. Turley, K. Gatter, P. G. Petronini, S. B. Fox, A. L. Harris, M. Martinotti, A. BerrutiA. Bottini, A. R. Reynolds, D. Generali

Research output: Contribution to journalArticlepeer-review

Fingerprint Dive into the research topics of 'Combination of letrozole, metronomic cyclophosphamide and sorafenib is well-tolerated and shows activity in patients with primary breast cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences